Signant’s Bill Byrom, PhD, sat down with TransPerfect to discuss the impact of recent FDA draft guidance on instrument selection and measurement strategies for capturing patient-reported outcome (PRO) data in modern oncology trials.
The panelists also shared key considerations for trial designs that reduce patient burdens, examined the potential of item banks and augmentation of current tools, and explained the need for specificity of instruments to support labeling claims.
To tune into more oncology and eCOA expert insights, tune into the webinar recording below.
